NASH Target Development Service for RvD1 Analogues

Creative Biolabs is a professional CRO company that has developed a comprehensive service chain in drug discovery for NASH treatment. With in-depth expertise in molecular modeling, structural analysis, as well as in-vivo and in-vitro studies, we have successfully completed a number of projects on RvD1 based therapeutic strategies platform which enables us to offer a high screening service based on a full range of state-of-art technologies. We are dedicating to help our worldwide customers shorten development time at a low-cost manner.

Introduction of RvD1

RvD1, also known as resolvin D1, is a type of lipid mediators that are generated from an omega-3 polyunsaturated fatty acid. The studies have demonstrated that RvD1 can be produced by a wide variety of cells, such as leukocytes, macrophage as well as endothelial cells, and the RvD1 plays an important role in inhibiting the secretion of interleukin (IL)-1 and the progress of polymorphic neutrophil (PMN) infiltration, as well as improving phagocytosis of macrophages. It has been proved to be important to regulate the anti-inflammatory in various diseases. At present, many studies have revealed that RVD1 can promote the liver decomposition process by reducing the inflammatory component of nonalcoholic steatohepatitis (NASH) caused by obesity. In addition, RvD1 has been proved to be able to prevent liver damage caused by sodium and can stop the conversion of hepatitis to liver cancer by inhibiting the anti-inflammatory mediated cytokine and nuclear factor kappaB (NF-κB) and activator protein 1 (AP-1) activity, suggesting that it is an attractive target for discovering novel therapies against hepatitis, NASH and liver cancer.

Fig.1 Mechanism of specialized pro-resolving mediators (SPMs) in the resolution of NASH inflammation. (Schuster, 2018)

Our Platform for RvD1 Analogues

RvD1 has been regarded as an anti-inflammatory mediator in NASH therapy. Pilot studies have indicated that RvD1 can promote the fatty resolution by restricting calories in obese mice with NASH, and thereby providing a new sight for NASH therapy. Creative Biolabs has developed a series of platforms for our clients to offer a full range of drug discovery services targeting RvD1 or its analogues, including target identification, target validation, the safety evaluation as well as preclinical trials of animal models. Our seamless platform can span the entire drug discovery routine and get accurate data at a fast turnaround time. In addition, equipped with numerous technologies and experienced scientists, we will provide a reliable RvD1 based NASH drug discovery research, such as BDA-RvD1 and lipo-RvD1, as well as meet any requirement of your programs.

With over years of experience in drug discovery for NASH therapy, Creative Biolabs offers a large collection of assays for target screening from specificity to safety services. Our client-focused, integrated team anticipate challenge, overcome difficulties and can convert various potential targets into preclinical trials. For more information, please feel free to contact us or send us an inquiry.

Reference

1. Schuster, S.; et al. Triggering and resolution of inflammation in NASH. Nature Reviews Gastroenterology & Hepatologyvolume. 2018, 15: 349-364.